KalVista Pharmaceuticals, Inc. (KALV) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
KALV currently has 54.6M outstanding shares. with limited dilution risk as only 4.79M additional shares (8.8%) are authorized for issuance. The company has significantly diluted shareholders by 33.08% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 14, 2026 |
10-Q filing | 54.6M shares outstanding |
55M | 4.8M |
| Nov 10, 2025 |
10-Q filing | 53.9M shares outstanding |
54M | 5.5M |
| Sep 11, 2025 |
10-Q filing | 53.5M shares outstanding |
53M | 5.9M |
| Jul 10, 2025 |
10-K filing | 49.7M shares outstanding |
50M | 9.7M |
| Mar 12, 2025 |
10-Q filing | 52.6M shares outstanding |
53M | 6.7M |
| Dec 05, 2024 |
10-Q filing | 46.7M shares outstanding |
47M | 13M |
| Sep 05, 2024 |
10-Q filing | 46.2M shares outstanding |
46M | 13M |
| Jul 11, 2024 |
S-3 filing: KalVista Pharmaceuticals intends to offer up to $300 million in shares of common stock, preferred stock, debt securities, warrants, subscription rights and units. |
42M | 17M |
| Jul 11, 2024 |
10-K filing | 42.7M shares outstanding |
43M | 17M |
| Mar 11, 2024 |
10-Q filing | 42.2M shares outstanding |
42M | 0 |
| Dec 07, 2023 |
10-Q filing | 34.6M shares outstanding |
35M | 940K |
| Sep 07, 2023 |
10-Q filing | 34.4M shares outstanding |
34M | 1.1M |
| Jul 10, 2023 |
10-K filing | 34.2M shares outstanding |
34M | 1.3M |
| Mar 09, 2023 |
10-Q filing | 34.2M shares outstanding |
34M | 1.3M |
| Dec 08, 2022 |
10-Q filing | 24.6M shares outstanding |
25M | 11M |
| Sep 08, 2022 |
10-Q filing | 24.6M shares outstanding |
25M | 11M |
| Jul 07, 2022 |
10-K filing | 24.5M shares outstanding |
24M | 11M |
| Mar 10, 2022 |
10-Q filing | 24.5M shares outstanding |
25M | 11M |
| Dec 09, 2021 |
10-Q filing | 24.5M shares outstanding |
24M | 11M |
| Sep 09, 2021 |
10-Q filing | 24.4M shares outstanding |
24M | 11M |
| Jul 13, 2021 |
10-K filing | 24.4M shares outstanding |
24M | 11M |
| May 21, 2021 |
S-3 filing: KalVista Pharmaceuticals, Inc. may offer up to $300,000,000 aggregate dollar amount of shares of its common stock or preferred stock, debt securities, warrants to purchase its common stock, preferred stock or debt securities, subscription rights to purchase its common stock, preferred stock or debt securities and/or units consisting of some or all of these securities. |
24M | 11M |
| Mar 11, 2021 |
10-Q filing | 24.3M shares outstanding |
24M | 0 |
| Dec 10, 2020 |
10-Q filing | 17.9M shares outstanding |
18M | 0 |
| Sep 14, 2020 |
10-Q filing | 17.9M shares outstanding |
18M | 0 |
| Jul 01, 2020 |
10-K filing | 17.8M shares outstanding |
18M | 0 |
| Mar 10, 2020 |
10-Q filing | 17.8M shares outstanding |
18M | 0 |